Author Guidelines
Acta Anaesthesiologica Scandinavica publishes original work in the fields of anaesthesiology, intensive care, pain, and emergency medicine. This includes clinical or laboratory investigations, review articles, case reports and letters to the Editor.
Manuscripts will be reviewed on the understanding that they have not been published, simultaneously submitted or accepted for publication elsewhere. It is expected that the work presented has been performed in accordance with the most recent version of the Helsinki Declaration and it should be stated in the manuscript that necessary permission has been obtained from the appropriate ethics committee. The following information must be reported: the name and address of the ethics committee responsible; the protocol number that was attributed by this ethics committee and the date of approval by the ethics committee.
Approvals from other relevant, national bodies must also be declared. The Editorial Board may exercise judgment about the ethics of a clinical trial involving investigational drugs that is more stringent than the investigator’s ethics committee, especially in studies of drugs in children and if the dose, route of administration, and indication do not match the guidelines in the package insert (“off-label”), for instance related to neuraxial administration. Reports of investigations in animals will not be accepted for publication unless the text states that the study was approved by the appropriate animal investigation committee.
The journal strongly recommends that authors use and adhere to the proper reporting guideline that is appropriate for their study. The common different types of studies include, but are not limited to, the following: Randomised trials- CONSORT, Observational studies- STROBE, Systematic reviews- PRISMA, Diagnostic/prognostic studies- STARD. Quality improvement studies- SQUIRE, Economic evaluations- CHEERS, Animal pre-clinical studies- ARRIVE, Study protocols- SPIRIT, Clinical practice guidelines- AGREE. Also, related to each of these reporting guidelines, there can be specialized reporting guidelines for specialised study designs. One source that coordinates access to these on a single website is this one (www.equator-network.org). Please use the appropriate reporting guidelines to help prepare your manuscript before you submit it. We strongly recommend that authors submit the completed guideline reporting checklist as a supplemental document along with their manuscript. If this is not submitted, it may be requested.
Preprint policy
This journal will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.
Data Sharing and Data Accessibility
This journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.
All accepted manuscripts may elect to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data.
Sample statements are available here. If published, statements will be placed in the heading of your manuscript.
We also encourage authors to submit the complete, relevant data files as a supplemental document/file, along with their manuscript, which, with author permission, can be made available to readers as a supplementary file with the digital version of a publication in our journal.
Registration of Clinical Trials
This is relevant for clinical trials if patient enrolment began after January 1, 2010. Research is considered to be a clinical trial if it involves prospective assignment of human subjects to an intervention or comparison group to study the relation between a health-related intervention and a health outcome. Trials must be registered before recruitment of the first subject in a public trials registry that can be assessed by the editors, the reviewers, and the readers.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, and managed by a not-for-profit organization. The registry must include the following information: a unique identifying number, a statement of the intervention(s), study hypothesis, definition of primary and secondary outcome measurements, eligibility criteria, target number of subjects, funding source, contact information for the principal investigator, and key dates (registration date, start date, and completion date). The following registries are recommended: Clinical Trials, ISRCTN Register, UMIN Clinical Trials Registry, Australia New Zealand Clinical Trials Registry, Nederlands Trial Register.
Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in the article and we ask that you include the URL and identification number on the title page of your manuscript.
Acta Anaesthesiologica Scandinavica employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Ithenticate
Online Submission System
To access the online system for submission and review, go directly to http://mc.manuscriptcentral.com/aas.
Submission form
All submissions must include a completed Submission Form that has been signed by all authors. If you do not provide this form your manuscript will not be sent for review. Please upload a scan of the completed and signed form as a 'supplemental file not for review' when submitting your manuscript.
ORCID
As part of the journal’s commitment to supporting authors at every step of the publishing process, this journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Please see Wiley’s resources on ORCID here.
Patient Consent Form
Images of, or information about, identifiable individuals: It is the author’s responsibility to obtain consent from patients and other individuals for use of information, images, audio files, interview transcripts, and video clips from which they may be identified. To ensure we have the rights, we require a signed consent/release form in all instances. Please find the form here. If the person is a minor, consent must be obtained from the child’s parents or guardians.
If the person is a minor, consent must be obtained from the child’s parents or guardians
If the person is dead, we consider it essential and ethical that you obtain consent for use from the next of kin. If this is impractical you need to balance the need to use the photo against the risk of causing offence. In all cases ensure you obscure the identity of the deceased.
If using older material, or for material obtained in the field, for which signed release forms are, for practical purposes, unobtainable, you will need to confirm in writing that the material in question was obtained with the person’s understanding that it might be published.
Open Access is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of the article. With Open Access, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive.
For more information on Open Access including the full list of terms and conditions and the online order form please go to here.
Prior to acceptance there is no requirement to inform and Editorial Office that you intend to publish your paper Open Access if you do not wish to do so. All Open Access articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected on their own merit.
Copyright
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the CTA
If the Open Access option is not selected the corresponding author will be presented with the CTA to sign. The terms and conditions of the CTA can be previewed below:
CTA Terms and Conditions. Please do not complete this PDF until you are prompted to login into Author Services as described above.
Note to Contributors on Deposit of Accepted Version
Funder arrangements
Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a repository after an embargo period. Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement. Please contact the Journal production editor if you have additional funding requirements.
Institutions
Wiley has arrangements with certain academic institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://www.wiley.com/go/funderstatement
For authors choosing Open Access
If the Open Access option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the Open Access option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:
Creative Commons Attribution License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
Manuscript preparation
Manuscripts should be prepared and submitted in accordance with: 'Uniform requirements for manuscripts submitted to biomedical journals' (http://www.icmje.org/) We recommend authors to have a look at a recent issue concerning abbreviations, units, figures, and tables.
Manuscripts should normally not exceed 3000 words (excl. abstract, tables, figures, and references), and should be divided into the following sections:
The title page (pg. 1) with a short and informative title (preferably less than 15 words and please avoid abbreviations in the title), the names of the authors (first name, initials (if any) and last name, no titles), the name and location of the institutions where the work was carried out, a short title of no more than 40 letters and spaces, a word count (excl. abstract and references) and the name, jobtitle and address (including tel., fax. and e-mail address) of the author to whom correspondence should be addressed. Any relevant conflict of interest must be described in the manuscript in a footnote on the title page.
Abstract (on a separate page (page 2). The abstract must not exceed 250 words. Abstracts should be structured as follows: background, methods, results and conclusion. Each part of the abstract should start on a new line. Abbreviations should normally not be used in the abstract.
Introduction starts on the third page. In all manuscripts reporting original research, a specific hypothesis or research question and aim of study should be clearly stated at the end of this section.
Methods section starts with a new page. Reports of randomised trials must conform to the CONSORT guidelines. For such studies, a flow diagram should be a part of the manuscript and a completed Consort Checklist must be submitted with the manuscript (can be downloaded from the journal homepage). For other types of studies, the CONSORT checklist is also very useful to consult. Primary and possible secondary outcome measures must be thoroughly defined, including how and when they were assessed. Detailed statistical methodology must be reported. Describe the specific tests used to examine the primary outcome measure and also the methods for additional analyses such as subgroup analyses and multiple comparisons. Variability should be expressed either as median with range (or percentiles) for nonparametric data, or mean with standard deviation for normally distributed data. Proportions should be reported with 95% confidence interval. A sample size calculation based on the primary outcome with description of statistical power is required. It must be described how the authors determined the clinically relevant difference to be detected.
Results section should start with a new page. Results related to the primary outcome must be quantified, whether statistically significant or not. This can, as an example, be accomplished by reporting differences with 95% confidence interval.
Discussion section starts with a new page and describes strengths and limitations of the study, interpretation of results, and relation to current evidence. The section should summarise the most important finding in the first paragraph and a conclusion at the end.
Acknowledgements. Individuals thanked must accept this in a signed statement that should be sent with the covering letter. All funding must be reported in the acknowledgements section, even if only to say “Departmental funding only”. An explicit statement is needed in all manuscripts regarding author conflict of interest, even if only to say “The authors have no conflicts of interest”.
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/13996576/homepage/forauthors.html
